


Phytotherapy in the Management of Diabetes and Hypertension



Editor:
Mohamed Eddouks

Bentham Books

Phytotherapy in the Management of Diabetes and Hypertension

(Volume 3)

Edited by

Mohamed Eddouks

Faculty of Sciences and Techniques Errachidia

Moulay Ismail University of Meknes

Errachidia

Morocco

Rj { vqvj gter { 'lp'vj g'O cpci go gpv'qhF kcdgvgu'bpf 'J { rgt vgpukqp

Volume # 3

Editor: Mohamed Eddouks

ISSN (Online): 2452-3232

ISSN (Print): 2452-3224

ISBN (Online): 978-981-14-5913-9

ISBN (Print): 978-981-14-5911-5

ISBN (Paperback): 978-981-14-5912-2

© 2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 BIOCHEMISTRY OF TYPE 2 DIABETES MELLITUS	1
<i>Ekambaram Sanmuga Priya, Perumal Senthamil Selvan and Erusappan Thamizharasi</i>	
INTRODUCTION	1
EPIDEMIOLOGY OF T2DM	2
ETIOLOGY OF T2DM	2
SOME MAJOR CAUSES OF DEVELOPING INSULIN RESISTANCE INCLUDE	3
PATHOPHYSIOLOGY OF T2DM	4
GENETIC FACTORS ASSOCIATED WITH T2DM	6
B CELL DYSFUNCTION AND INSULIN RESISTANCE	7
ROLE OF INCRETINS	8
INSULIN RESISTANCE MECHANISMS	8
PLEIOTROPIC ACTION OF INSULIN	13
ROLE OF INSULIN IN CARBOHYDRATE METABOLISM	14
ROLE OF INSULIN IN LIPID METABOLISM	14
ROLE OF INSULIN IN PROTEIN METABOLISM	14
BIOCHEMISTRY OF GLUCOSE UPTAKE	14
INTRODUCTION TO THE INSULIN RECEPTOR (IR)	15
INSULIN SIGNALING	15
MITOGENIC PATHWAY (RAS/MAP KINASE)	17
METABOLIC PATHWAY (PI3K/AKT)	17
REGULATION OF GLUT 4 TRANSLOCATION	18
PROTEIN KINASE C	20
INSULIN SIGNALING: NEGATIVE REGULATORS	20
INSULIN SIGNALING: ABNORMALITIES	21
INDEPENDENT PATHWAYS FOR GLUCOSE TRANSPORT (CAP/CBL/TC10)	23
THERAPEUTICS OF T2DM	24
FUTURE AREAS OF RESEARCH	26
CONCLUSION	28
CONSENT FOR PUBLICATION	29
CONFLICT OF INTEREST	29
ACKNOWLEDGEMENTS	29
REFERENCES	29
CHAPTER 2 DIABETES MELLITUS AND PROTECTIVE APPROACHES OF MEDICINAL PLANTS: PRESENT STATUS AND FUTURE PROSPECTS	38
<i>Maliha Sarfraz</i>	
DIABETES MELLITUS	38
Pathophysiology and Complications	39
Effects of Diabetes Mellitus on Biological Parameters	39
Diabetes Mellitus Management	40
Conventional and Traditional Treatments for Diabetes	40
DIABETES AND BOTANICAL MEDICINES	41
NOMENCLATURE AND CHEMICAL CONSTITUENTS OF MEDICINAL PLANTS	42
PROTECTIVE EFFECT OF MEDICINAL PLANTS	44
FUTURE PROSPECTIVE	52
CONSENT FOR PUBLICATION	53

CONFLICT OF INTEREST	53
ACKNOWLEDGEMENT	53
REFERENCES	53
CHAPTER 3 ANTI-DIABETIC AND ANTI-HYPERTENSIVE POTENTIALS OF ESSENTIAL OIL BEARING MEDICINAL PLANTS	61
<i>Farwa Nadeem, Muhammad Asif Hanif, Asma El Zerey-Belaskri, Muhammad Irfan Majeed and Haq Nawaz</i>	
INTRODUCTION	61
BIOCHEMISTRY OF DIABETES MELLITUS	66
BIOCHEMISTRY OF HYPERTENSION	68
ANTI-DIABETIC PLANTS	68
Alkanet (<i>Anchusa officinalis</i> L.)	69
Asthma Weed (<i>Euphorbia hirta</i> L.)	69
Bamboo (<i>Bambusa arundinacea</i>)	69
Basil (<i>Ocimum basilicum</i> L.)	70
Caraway (<i>Carum carvi</i> L.)	70
Chirayita (<i>Swertia chirayita</i>)	70
Coleus (<i>Coleus forskohlii</i>)	71
Cubeb (<i>Piper cubeba</i>)	71
Cumin (<i>Cuminum cyminum</i>)	71
Cypress (<i>Cupressus sempervirens glauca</i>)	71
Damask Rose (<i>Rosa damascena</i> Mil.)	72
Fennel (<i>Foeniculum vulgare</i>)	72
Fenugreek (<i>Trigonella foenum-groecum</i> L.)	72
Fig (<i>Ficus carica</i> L.)	72
Frangipani (<i>Plumeria rubra</i> L.)	73
Ginseng (<i>Panax ginseng</i>)	73
Guava (<i>Psidium guajava</i> L.)	73
Henna (<i>Lawsonia inermis</i> L.)	74
Indian Globe Thistle (<i>Sphaeranthus indicus</i>)	74
Indian Pennywort (<i>Centella asiatica</i>)	74
Ma-huang (<i>Ephedra gerardiana</i>)	74
Moringa (<i>Moringa oleifera</i> L.)	75
Olive (<i>Olea europaea</i> L.)	75
Puncture Vine (<i>Tribulus terrestris</i>)	75
Saffron (<i>Crocus sativus</i>)	75
Sweet Lemon (<i>Citrus limetta</i> Risso)	76
Tree Turmeric (<i>Berberis aristata</i>)	76
Walnut (<i>Juglans regia</i> L.)	77
Corn (<i>Zea mays</i>)	77
Tawa Tawa (<i>Euphorbia hirta</i>)	77
ANTI-HYPERTENSIVE PLANTS	79
Basil (<i>Ocimum basilicum</i> L.)	80
Black piper (<i>Piper nigrum</i> L.)	80
Coleus (<i>Coleus forskohlii</i>)	80
Curry Leaf (<i>Murraya koenigii</i> L.)	81
Puncture Vine (<i>Tribulus terrestris</i>)	81
Sesame Seed (<i>Sesamum indicum</i> L.)	81
Yarrow (<i>Achillea wilhelmsii</i>)	82
Passion Fruit (<i>Passiflora edulis</i>)	82

Onion (<i>Allium cepa</i>)	82
Garlic (<i>Allium sativum</i>)	83
Celery (<i>Apium graveolens</i>)	83
Oat (<i>Avena sativa</i> L.)	83
Barberry (<i>Berberis vulgaris</i>)	84
Black Cumin (<i>Nigella sativa</i>)	84
Ylang-Ylang (<i>Cananga odorata</i> L.)	84
Garden Cress (<i>Lapidium sativum</i> L.)	84
Ginger (<i>Zingiber officinale</i>)	85
Sweet Lemon (<i>Citrus limetta</i> Risso)	85
CONCLUDING REMARKS	85
CONSENT FOR PUBLICATION	86
CONFLICT OF INTEREST	86
ACKNOWLEDGEMENT	86
REFERENCES	86

CHAPTER 4 MANAGEMENT OF DIABETES MELLITUS BY NATURAL PRODUCTS:

GLUCAGON-LIKE PEPTIDE 1 PERSPECTIVE	95
<i>Ojaskumar D. Agrawal</i> <i>cpf Yogesh A. Kulkarni</i>	
INTRODUCTION	95
Glucagon-Like Peptide - 1	96
Secretion of Incretin Hormones in Healthy Human Subjects	97
1. Soybeans (<i>Glycine max</i> , Leguminosae)	98
2. Coffee (<i>Coffea arabica</i> , Rubiaceae)	99
3. Bitter melon (<i>Momordica charantia</i> , Cucurbitaceae)	101
4. Gentian (<i>Gentiana scabra</i> , Gentianaceae)	101
5. Chicory Roots (<i>Cichorium intybus</i> , Asteraceae)	103
6. Cinnamon (<i>Cinnamomum zeylanicum</i> , Lauraceae)	103
7. Gardenia fruit (<i>Gardenia jasminoides</i> , Rubiaceae)	104
8. Korean Pine Nut (<i>Pinus koraiensis</i> , Pinaceae)	106
9. A little dragon (<i>Artemisia dracunculus</i> , Asteraceae)	106
10. Mango (<i>Mangifera indica</i> , Anacardiaceae)	106
11. Wheat (<i>Triticum aestivum</i> , Poaceae)	107
12. Yacon Root (<i>Smallanthus sonchifolius</i> , Asteraceae)	107
13. Pygeum (<i>Prunus africanum</i> , Rosaceae)	108
14. Turmeric (<i>Curcuma longa</i> , Zingiberaceae)	108
15. Barberry (<i>Berberis vulgaris</i> , Berberidaceae)	109
16. Agave (<i>Agave tequilana</i> , Agavaceae)	111
17. Olive oil (<i>Olea europaea</i> , Oleaceae)	111
18. Grape-Seed (<i>Vitis vinifera</i> , Vitaceae)	111
19. Green Tea (<i>Camellia sinensis</i> , Theaceae)	112
20. Mate tea (<i>Ilex paraguariensis</i> , Aquifoliaceae)	112
21. Butyrate and Propionate	113
22. Palatinose Disaccharide	114
23. Whey protein	114
24. Fructose	115
25. Peanut (<i>Arachis hypogaea</i> , Fabaceae)	116
CONCLUSION	116
CONSENT FOR PUBLICATION	117
CONFLICT OF INTEREST	117
ACKNOWLEDGEMENT	117

REFERENCES	117
CHAPTER 5 TERPENES AND TERPENOIDS IN MANAGEMENT OF DIABETES & CARDIOVASCULAR DISEASES	127
<i>Kaveri M. Adki, Ankit P. Laddha, Manisha J. Oza, Anil Bhanudas Gaikwad cpf Yogesh A. Kulkarni</i>	
INTRODUCTION	128
Interconnection between Diabetes and Cardiovascular Diseases	129
Terpenoids	131
Isoprene Unit	131
Hemiterpenes	132
Monoterpenes	132
Sesquiterpenes	133
Diterpenes	134
Sesterpenes	135
Triterpenes	135
Tetraterpenes	136
Polyterpenes	136
Meroterpenes	136
Biosynthesis of Terpenoids	137
Terpenoids in Diabetes and Cardiovascular Diseases	139
1. Lupeol	139
<i>Lupeol in Diabetes</i>	139
<i>Lupeol in Cardiovascular Diseases</i>	141
2. Limonene	143
<i>Limonene in Diabetes</i>	143
<i>Limonene in Cardiovascular Diseases</i>	144
3. Arjunolic Acid	145
<i>Arjunolic Acid in Diabetes</i>	145
<i>Arjunolic Acid in Cardiovascular Diseases</i>	146
4. Ursolic Acid	147
<i>Ursolic Acid in Diabetes</i>	147
<i>Ursolic Acid in Cardiovascular Diseases</i>	148
5. Glycyrrhetic Acid	149
<i>Glycyrrhetic Acid in Diabetes</i>	149
<i>Glycyrrhetic Acid in Cardiovascular Diseases</i>	149
6. Ginsenoside	151
<i>Ginseosides in Diabetes</i>	151
<i>Ginsenosides in Cardiovascular Diseases</i>	152
7. Corosolic Acid	152
<i>Corosolic Acid in Diabetes</i>	153
<i>Corosolic Acid in Cardiovascular Diseases</i>	154
8. Pomolic Acid	155
<i>Pomolic Acid in Diabetes</i>	156
<i>Pomolic Acid in Cardiovascular Diseases</i>	156
CONCLUDING REMARKS	156
CONSENT FOR PUBLICATION	157
CONFLICT OF INTEREST	157
ACKNOWLEDGEMENTS	157
REFERENCES	157

CHAPTER 6 ANTIDIABETIC AND ANTIHYPERTENSIVE MEDICINAL PLANTS OF ASIA: ACTIVE INGREDIENTS, SAFETY, PHARMACOLOGY, AND TRADITIONAL USES	166
<i>Subrata Das, Anupam Das Talukdar, Manabendra Dutta Choudhury cfp Sanjoy Singh Ningthoujam</i>	
INTRODUCTION	166
Diabetes	166
Hypertension	167
Diabetes and Hypertension	168
ANTIDIABETIC MEDICINAL PLANTS OF ASIA AND THEIR ACTIVE INGREDIENTS IN TRADITIONAL USES	169
<i>Brassica juncea</i> (L.) Czern	169
<i>Syzygium cumini</i> (L.) Skeels	170
<i>Coccinia grandis</i> (L.) Voigt	170
<i>Alangium salviifolium</i> (L.f.) Wangerin	170
<i>Albizia odoratissima</i> (L.f.) Benth	170
<i>Axonopus compressus</i> (Sw.) P.Beauv	171
<i>Berberis vulgaris</i> L.	171
<i>Caesalpinia digyna</i> Rottler	171
<i>Catharanthus roseus</i> (L.) G.Don	171
<i>Centaurium erythraea</i> Rafn	172
<i>Aeglemarmelos</i> (L.) Correa	172
<i>Allium cepa</i> L.	172
<i>Allium sativum</i> L.	173
<i>Aloe vera</i> (L.) Burm. F.	173
<i>Andrographispaniculata</i> (Burm. F.) Nees	173
<i>Annona squamosa</i> L.	173
<i>Azadirachtaindica</i> A. Juss	174
<i>Cinnamomumtamala</i> (Buch. -Ham.) T. Nees & Eberm	175
ANTIHTERTENSIVE MEDICINAL PLANTS OF ASIA AND THEIR ACTIVE INGREDIENTS IN TRADITIONAL USES	176
<i>Apiumgraveolens</i> L.	176
<i>Aristolochia manshuriensis</i> Kom	176
<i>Avena sativa</i> L.	176
<i>Plantagoovata</i> Forssk	177
<i>Camellia sinensis</i> (L.) Kuntze	177
<i>Trachyspermumammi</i> (L.) Sprague	177
<i>Chamaecristaabsus</i> (L.) H.S.Irwin & Barne by	178
<i>Sennaoccidentalis</i> (L.) Link	178
<i>Coleus forskohlii</i> (Willd.) Briq	178
<i>Cuscuta reflexa</i> Roxb	178
CONCLUSION	180
CONSENT FOR PUBLICATION	180
CONFLICT OF INTEREST	180
ACKNOWLEDGEMENTS	180
REFERENCES	180
CHAPTER 7 CHRYSOPHYLLUM CAINITO L.	189
<i>A. Sánchez-Recillas, L. Cerón-Romero, R. Ortiz-Andrade cfp J.C. Sánchez-Salgado</i>	
INTRODUCTION	189
SYNONYMS	190
BOTANICAL FEATURES [3]	190

VERNACULAR NAMES	190
DISTRIBUTION	192
CHEMICAL CONSTITUENTS	192
PURITY REQUIREMENTS	197
Fruit Composition	197
CHEMICAL ASSAYS	198
MEDICINAL USES	199
PHARMACOLOGY	199
Experimental Pharmacology	199
TOXICITY	205
CONTRAINDICATIONS	206
PRECAUTIONS AND WARNINGS	206
Surgery	206
CONCLUSION	206
CONSENT FOR PUBLICATION	206
CONFLICT OF INTEREST	206
ACKNOWLEDGEMENTS	206
REFERENCES	206
SUBJECT INDEX	211

PREFACE

The volume 1 of the present ebook series “Phytotherapy in the Management of Diabetes and Hypertension” has emphasized the basic Biochemistry of diabetes mellitus and hypertension, and described many aspects of these lifestyle diseases and its control or remediation through a cost effective, safe, easy-going, easy-adaptable method through the age-old practice validated by scientific research. In response to requests from WHO in providing safe and effective herbal medicines for use in national health-care systems and to prepare monographs of used medicinal plants around the world, the volume 2 of this e-book series has been published in 2016 and contained monographs related to antihypertensive and antidiabetic plants. The present volume 3 is dedicated to different aspects including the evaluation of the efficacy and safety of medicinal plants and their derivatives on diabetes and hypertension. The study of the mechanisms of action of medicinal plants is deeply discussed. This volume includes 7 complementary chapters that describe different aspects including the biochemistry of type 2 diabetes, the pathophysiology of diabetes and hypertension, the role of essential oils extracted from medicinal plants in the management of diabetes and hypertension, the mechanistic perspectives of the treatment of diabetes and hypertension, some important phytochemicals with beneficial action on diabetes and hypertension, and detailed monographs concerning some potential medicinal plants used in the treatment of diabetes and hypertension. This volume will be useful to the students, teachers, researchers, scientists, clinicians, herbalists, and even the common people interested to know about the subject.

ACKNOWLEDGMENTS AND GRANTS

The Editor would like to express his thanks to all the authors, the reviewers, and Miss Salma Sarfraz for their special effort during the preparation of this book. This work was supported by the Ministry of National Education, Vocational Training, Higher Education and the Scientific Research (Morocco) and the National Center for Scientific and Technical Research (CNRST) (Morocco) under grant N° PPR/2015/35.

Mohamed Eddouks
Faculty of Sciences and Techniques Errachidia
Moulay Ismail University of Meknes
Errachidia
Morocco

List of Contributors

- Adki Kaveri M.** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (West), Mumbai-400056, India
- Agrawal Ojaskumar D.** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L Mehta Road, Vile Parle (W), Mumbai – 400 056, India
Vivekanand Education Society's College of Pharmacy, University of Mumbai, Chembur (E), Mumbai 400074, India
- Cerón-Romero L.** Laboratorio de Farmacología, Facultad de Química, Universidad autónoma de Yucatán, Calle 43 No. 613 x Calle 90 Col. Inalámbrica. C.P. 97069, Mérida, Yucatán, Mexico
- Choudhury Manabendra Dutta** Department of Life Science and Bioinformatics, Assam University, Silchar, India
- Das Subrata** Department of Life Science and Bioinformatics, Assam University, Silchar, India
- Ekambaram Sanmuga Priya** Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli – 620 024, Tamil Nadu, India
- El Zerey-Belaskri Asma** Laboratoire de recherche Biodiversité végétale: conservation et valorisation, Faculté des Sciences de la nature et de la Vie, Université de Sidi Bel Abbes, Algérie
- Erusappan Thamizharasi** Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli – 620 024, Tamil Nadu, India
- Gaikwad Anil Bhanudas** Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus Pilani- 333031, Rajasthan, India
- Hanif Muhammad Asif** Nano and Biomaterials Lab, Department of Chemistry, University of Agriculture, Faisalabad-38040, Pakistan
- Kulkarni Yogesh A.** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L Mehta Road, Vile Parle (W), Mumbai – 400 056, India
- Laddha Ankit P.** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (West), Mumbai-400056, India
- Majeed Muhammad Irfan** Department of Chemistry, University of Agriculture, Faisalabad-38040, Pakistan
- Nadeem Farwa** Nano and Biomaterials Lab, Department of Chemistry, University of Agriculture, Faisalabad-38040, Pakistan
- Nawaz Haq** Nano and Biomaterials Lab, Department of Chemistry, University of Agriculture, Faisalabad-38040, Pakistan

- Ningthoujam Sanjoy Singh** Department of Botany, Ghanapriya Women's College, Dhanamanjuri University, Imphal, India
- Ortiz-Andrade R.** Laboratorio de Farmacología, Facultad de Química, Universidad autónoma de Yucatán, Calle 43 No. 613 x Calle 90 Col. Inalámbrica. C.P. 97069, Mérida, Yucatán, Mexico
- Oza Manisha J.** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (West), Mumbai-400056, India
SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V.L. Mehta Road, Vile Parle (West), Mumbai-400056, India
- Perumal Senthamil Selvan** Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli – 620 024, Tamil Nadu, India
- Sánchez-Recillas A.** Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Calle 43 No. 613 x Calle 90 Col. Inalámbrica. C.P. 97069, Mérida, Yucatán, Mexico
- Sarfraz Maliha** Institute of Pharmacy, Physiology and Pharmacology, Department of Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan
- Talukdar Anupam Das** Department of Life Science and Bioinformatics, Assam University, Silchar, India

CHAPTER 1

Biochemistry of Type 2 Diabetes Mellitus

Ekambaram Sanmuga Priya^{*}, Perumal Senthamil Selvan and Erusappan Thamizharasi

Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli, India

Abstract: Diabetes mellitus, a metabolic disorder, characterized by chronic hyperglycemia results from defects in insulin secretion, insulin action, or both. Insulin is an anabolic peptide hormone that possesses pleiotropic activity. It can hinder with multiple physiological processes by either upregulating or downregulating various metabolic intracellular pathways. The complex insulin signaling system makes it vital in a variety of biological responses. This chapter describes the biochemistry of type 2 diabetes mellitus, as well as the features underlying its pathophysiology.

Keywords: Diabetes, Glucose Uptake, Insulin, Insulin Receptor, Insulin Resistance, Metabolic Disorder.

INTRODUCTION

Diabetes mellitus (DM), a metabolic disorder, characterized by chronic hyperglycemia results from defects in insulin secretion, insulin action, or both. Diabetes mellitus is classically characterized into two types *viz.* Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). T1DM, which is also known as insulin dependent diabetes mellitus (IDDM), is caused due to deficiency of insulin secretion from β cells of the pancreas. T2DM, which is also known as non-insulin dependent diabetes mellitus (NIDDM), is associated with diminished sensitivity of insulin in target tissues. This reduced sensitivity to insulin is a characteristic of insulin resistance. The reduced insulin levels or the resistance to insulin reduced the uptake of glucose by most of the tissues of the body except the brain [1]. This leads to an increase in blood glucose concentration along with a decrease in utilization of glucose by cells which results in an increase in the utilization of fats and proteins. The clinical features of patients with T1DM and T2DM are shown in Table 1.

^{*} **Corresponding author Ekambaram Sanmuga Priya:** Department of Pharmaceutical Technology, University College of Engineering, BIT Campus, Anna University, Tiruchirappalli, India; E-mail: sanmug77@gmail.com

Table 1. Clinical features of patients with T1DM and T2DM [1].

Features	T1DM	T2DM
Age of onset	Usually less than 20 years	Usually greater than 30 years
Body mass	Low (wasted) to normal	Obese
Plasma insulin	Low or absent	Normal to high initially
Plasma glucagon	High, can be suppressed	High, resistant to suppression
Plasma glucose	Increased	Increased
Insulin sensitivity	Normal	Reduced
Therapy	Insulin	Weight loss, thiazolidinediones, metformin, sulfonylureas, insulin, DPP4 inhibitors, PPAR- γ agonists, incretins, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin)

EPIDEMIOLOGY OF T2DM

The number of people with T2DM is progressively increasing. According to the World Health Organisation (WHO), there were 422 million adults with diabetes worldwide in 2014. The prevalence in adults increased from 4.7% in 1980 to 8.5% in 2014, with a higher increase in low and middle-income countries compared to high-income ones [2]. Further, the International Diabetes Federation (IDF) estimates to have 374 million people at an increased risk of developing T2DM. Without any intervention to slow down this rise in T2DM, there will be at least 700 million people with diabetes by 2045. The demographics of T2DM and the percentage of the population by geographical location are illustrated in Fig. (1). The lower rate of diagnosis of diabetes and the difficult access to diabetes care in low- and middle-income countries lead to 90% of all diabetes-related premature deaths and, 87% of all diabetes-related deaths [3]. Consequently, high blood glucose causes almost 4 million deaths each year [2]. The demographic and geographic outline of diabetes worldwide is shown in Fig. (1).

ETIOLOGY OF T2DM

T2DM, the more prevalent form of diabetes, is a heterogeneous disorder triggered by a multitude of genetic factors related to diminished insulin secretion, insulin resistance and related factors, such as obesity, overeating, sedentary lifestyle, stress and aging [4]. This multifactorial disease involves numerous genes as well as environmental factors [5]. There is an acute need for insulin by the body in T2DM to avoid the ketoacidosis. Predominately it is not an autoimmune disorder. Also, there is no identification of the susceptible genes that may account for a predisposition to T2DM in most patients. This can be accounted to the

heterogeneity of the genes accountable for the susceptibility to T2DM.




Fig. (1). Demographic and geographic outline of diabetes.

SOME MAJOR CAUSES OF DEVELOPING INSULIN RESISTANCE INCLUDE

1. Obesity, especially accumulation of adipose tissue surrounding the viscera.
2. Mutations in insulin receptor genes.
3. Mutations of the peroxisome proliferator activator receptor- γ (PPAR- γ) genes.
4. Mutations that cause genetic obesity, *e.g.*, melanocortin receptor mutations.
5. Higher glucocorticoids, *e.g.*, Cushing's syndrome or steroid therapy.
6. Higher growth hormone (acromegaly).
7. Pregnancy leading to gestational diabetes.
8. Polycystic ovary disease (PCOD).
9. Hypertension, *i.e.* ($\geq 140/90$ mmHg)
10. HDL cholesterol level (< 35 mg/dL (0.90 mmol/L) or triglyceride level > 250 mg/dL (2.82 mmol/L) or both).
11. Acquired or genetic lipodystrophy associated with accumulation of lipids in liver.
12. Hemochromatosis.

Diabetes Mellitus and Protective Approaches of Medicinal Plants: Present Status and Future Prospects

Maliha Sarfraz*

Institute of Physiology and Pharmacology, University of Agriculture Faisalabad, Pakistan

Abstract: Diabetes mellitus is one of the major health problem worldwide, its incidence and mortality are increasing day by day. Conventional antidiabetic drugs are available with unavoidable side effects. On the other hand, medicinal plants act as an alternative source of antidiabetic agents. From ancient times, herbs and spices have been widely used in the food and for medicinal purposes. In culinary practices, these are used as colorant, preservatives, and flavor substitution. In medicine, oxidative stress and inflammation associated with noncommunicable diseases can be treated or managed through herbs and spices. Phytochemicals like carotenoids, phenolic compounds, sterols, terpenes, alkaloids, glucosinolates, and other sulfur-containing compounds may be responsible for their protective and therapeutic effects. In this modern era, it is necessary to inform consumers about the benefits of botanical compounds. Many herbal plants have potential health claims that are not significantly demonstrated. Since herbs and spices can be used to get better food value and human health, as functional food ingredients they are helpful to decrease the risk of chronic diseases. Much trial evidence for the use of herbal plants to treat diabetes mellitus has uniformly demonstrated safety. However, further studies are needed to explore the health beneficial effects of these herbal plants used for diabetes mellitus.

DIABETES MELLITUS

Diabetes includes a varied set of ailments categorized as the production of sufficient insulin or decreased sensitivity due to many reasons; chronically increased glucose concentration is one of the common characteristics. Due to this, several metabolic complications raised; in blood, increased ketone bodies due to stern insulin deficiency [1]. In the pathogenesis of diabetic complications, hyperglycemia plays a significant role and those people are at higher risk, who have poor glycemic control. Although in various studies it has been mentioned that the destruction of beta cells and insulin resistance are the major factors of

* **Corresponding author Maliha Sarfraz:** Institute of Physiology and Pharmacology, University of Agriculture Faisalabad, Pakistan; E-mail: maliha.sarfraz@yahoo.com

diabetes, several signaling pathways are also involved in diabetes as summarized in Fig. (1) [2].




Fig. (1). Representative mechanism involved in the development of diabetes mellitus. Glucagon-like peptide 1 (GLP-1); insulin receptor substrate 1 and 2 (IRS-1/2); mitogen-activated protein kinases (MAPK); AMP-activated protein kinase (AMPK); I κ B kinase (I κ B); protein kinase C (PKC); Rho-associated coiled-coil containing protein kinase (ROCK); protein kinase B (PKB); forkhead box protein O (Foxo); PI3K subunit (p85); phosphatidylinositol 3-kinase (PI3K); Glycogen synthase kinase-3b (GSK-3b).

Pathophysiology and Complications

The specific acute metabolic complications of diabetes mellitus are diabetic ketoacidosis, lactic acidosis, hyperosmolar non-ketotic coma and hypoglycemia. In addition to acute complications, the long-lasting consequences of diabetes mellitus are the progressive development of some severe complications like retinopathy with prospective blindness, nephropathy that can cause kidney failure, neuropathy and diabetic foot, *etc.* Persistent hyperglycemia in diabetes may result in macroangiopathy and microangiopathy that are considered to be poly etiological disorders. Diabetic patients are generally more prone to coronary artery disease, diabetic cardiomyopathy, peripheral vascular and cerebrovascular disease [3].

Effects of Diabetes Mellitus on Biological Parameters

In diabetic animals, a strong relationship exists between hyperglycemia and reduced body weight. Weight decreased may be due to body's inability to utilize

and storage of glucose which leads to malnourishment and weight loss [4]. Pancreatic beta cells produce insulin which helps glucose transportation across cell membrane. Insulin insufficiency disturb the transportation of glucose in blood as a result level increased in blood and urine [5]. Carbohydrate and fat metabolism is impaired during diabetes. In mammals, various sites of lipid metabolism are affected by insulin. In hyperglycemic state, lipid peroxidation alterations are very common which is related to free radicals. These radicals cause lipid disruption . They are also involved in diabetes complications. Antioxidants neutralize these radicals which prevent complications induced by diabetes in experimental animal models [6]. In hyperglycemic condition, increased lipid peroxidation and accumulation of its products is caused by oxidative stress. Adefegha and Ganiyu, reported that in alloxan-induced diabetic rats malondialdehyde levels increased as compared to normal rats. Imbalance between oxygen free radicals production and cell defense mechanism also cause destruction of liver and pancreatic tissues that leads to complications [7]. Ragavan and Krishnakumari, studied that in diabetic conditions liver sections revealed structural alterations (hepatocyte necrosis) due to insulin absence [8]. Moreover, Hashemnia described the degenerative changes in hepatocytes such as hepatic cord disorganization, congestion of central veins and infiltrated sinusoids in diabetic rats [9].

Diabetes Mellitus Management

Managing of a disease is very important. Several aspects, such as less physical activity, obesity, smoking and use of alcohol, effects the incidence of diabetes. Lifestyle modifications can reduce the risk of disease incidence. High fiberous and low total fats diet will prevent diabetes. WHO also recommended that improving factors of lifestyle like stay away from fatness lastly from hyperglycemia [10].

Conventional and Traditional Treatments for Diabetes

Diabetes is considered a global problem world widely. The purpose of its treatment to get better life and prevention from its complications. Most commonly for type 1 diabetes short and long acting insulin and for type 2 biguanides and sulfonylureas are used in allopathy. The sulfonylureas include tolbutamide, glibenclamide, chlorpropamide, glipizide, acetohexamide, gliclazide and tolazamide. Several factors have been involved in therapeutic effects of sulfonylureas for type II diabetic patients, including pancreatic and extrapancreatic. Sulfonylureas directly encourage release of insulin from the β -cells in the islets of Langerhans, and this effect does not require the existence of

CHAPTER 3**Anti-Diabetic and Anti-Hypertensive Potentials of Essential Oil Bearing Medicinal Plants****Farwa Nadeem¹, Muhammad Asif Hanif^{1,*}, Asma El Zerey-Belaskri², Muhammad Irfan Majeed¹ and Haq Nawaz¹**¹ Nano and Biomaterials Lab, Department of Chemistry, University of Agriculture, Faisalabad-38040-Pakistan² Laboratoire de recherche Biodiversité végétale: conservation et valorisation, Faculté des Sciences de la nature et de la Vie, Université de Sidi Bel Abbas, Algérie

Abstract: Medicinal plants have long been the area of great interest and a hot topic of current scientific investigations for the biochemists, chemists and pharmaceuticals. These researches play an important role in discovering the new natural resources and developing the potential drugs for the treatment of various unknown diseases. These drugs are supposed to have more effectiveness and no side effects unlike most other synthetically produced modern drugs. In accordance with the World Health Organization (WHO), approximately four billion people constituting eight percent population of the world, use herbal based natural drugs for the majority of primary health care problems. Diabetes mellitus and hypertension are the two most common diseases that sometimes also coexist and enhance the chances of neuropathic disorders, brain strokes, retinopathic symptoms, peripheral vascular diseases and cardiac arrest. This chapter describes various medicinal plants having anti-diabetic and anti-hypertensive potentials along with their detailed mechanisms and mode of actions. Some potential anti-diabetic plants are alkanet, asthma weed, bamboo, basil, caraway, chirayita, coleus, cubeb, cumin, cypress, damask rose, fennel, fenugreek, fig, frangipani, ginseng, guava, henna, Indian globe thistle, Indian pennywort, ma-huang, moringa, olive, puncture vine, saffron, sweet lemon, tree turmeric, walnut, corn and tawa tawa. Anti-hypertensive plants discussed in this chapter include basil, black piper, coleus, curry leaf, puncture vine, sesame seed, yarrow, passion fruit, onion, garlic, celery, oat, barberry, black cumin, ylang ylang, garden cress, ginger and sweet lemon.

Keywords: Anti-diabetic, Anti-hypertensive, Brain Stroke, Cardiac Arrest, Essential oils, Medicinal Plants.

INTRODUCTION

Mother-nature has provided us a complete store-house of remedies in order to

* **Corresponding Author Muhammad Asif Hanif:** Nano and Biomaterials Lab, Department of Chemistry, University of Agriculture, Faisalabad-38040-Pakistan; E-mail: drmuhammadasifhanif@gmail.com

cure all sorts of ailments, proving to be catastrophic for human races. According to an estimate, a major portion of the world's population utilizes medicinal plants either in parts or as a whole plant [1]. Some additional medicinal uses of curative plants are recognized to learn more about the potential future perspective of medicinal plants. Medicinal remedies derived from plants, either by getting information through traditional knowledge or by exploring literature, are now being handed down generation after generation. Various pharmaceutical industries are now looking for some other natural alternative resources proven to be environmentally benign and potentially viable in nature. Nowadays, scientists are working to explore the potential anti-biotic, anti-oxidant, anti-microbial, anti-diabetic and crop protecting agents for the sustenance of all life forms on earth. Medicinal plants generally provide a great source of a wide variety of natural bioactive compounds including phenolics, nitrogenous compounds, terpenoids, vitamins and various other secondary plant metabolites showing potential bioactivities *e.g.*, anti-oxidants, anti-tumor, anti-inflammatory, anti-mutagenic, anti-bacterial, anti-carcinogenic and anti-viral activities [1].

Essential oils are the natural, complex, volatile aromatic compounds containing a number of structurally different organic constituents isolated from different scented plants having high commercial importance and extreme therapeutic potentials. Essential oils have extensively been used as a potential ingredient in order to enhance the functionality of a number of commercial products like green pesticides, cosmetic products, pharmaceuticals, perfumes, soft drinks and food stuff. Currently, global research is mainly focused on the development of eco-friendly techniques and innovative ideas for the extraction of essential oils and to stabilize them through proper encapsulation for bringing the natural products under the label of generally-recognized-as-safe. Essential oil is a biochemical product and a mixture of a large number of structurally related compounds, produced inside the cytoplasmic fluid and are then transported into intracellular space in the form of smaller droplets. These chemical compounds are highly volatile in nature and have a characteristic aroma. They are generally composed of a combination of aromatic and non-aromatic compounds having specific chemical composition and characteristic aroma [2].

Aromatic oils or scents contain approximately more than two hundred known complex chemical compounds having hydrogen, oxygen and carbon as the backbone of all complicated molecules. Essential oils can be broadly classified as (i) volatile and (ii) non-volatile components. Approximately 90 to 95 percent chemical constituents of essential oils such as alcohols, aliphatic compounds, esters, aldehydes, monoterpenes, sesquiterpenes and hydrocarbons along with their oxygenated derivative, are highly volatile in nature. Only 1 to 10 percent of molecules out of total weight are non-volatile in nature including hydrocarbons,

sterols, waxes, fatty acids, carotenoids and flavonoids. Chemical composition of the essential oils significantly changes with the duration of the growth period, environmental conditions, harvesting time and extraction technique. Composition of an essential oil significantly varies by changing the plant source and chemical constituents can range from a few dozens to hundreds of complex molecules. Oxygenated derivatives of hydrocarbons are accountable for the flavors and fragrances while higher phenolic contents help to improve the antibacterial activities [3].

The aromatic oils contain natural anti-oxidants that restrict the free radical reactions of deoxyribonucleic acid (DNA), unsaturated lipids, amino acids and proteins. Human body is known to have a strong defense mechanism against free radicals abundantly found in most of the body cells. The balance between the amount of antioxidants and free radicals can only be achieved by an external supply of natural or synthetic anti-oxidants. Scented aromatic oils are richly supplied with phenolic compounds that significantly contribute to determining free radical scavenging activities and anti-oxidant potentials. Essential oils of thyme, oregano, nutmeg, clove, cinnamon and basil are known to have strong anti-oxidant and free radical scavenging potentials in DPPH radical assay [4]. Some essential oils have strong anti-bacterial potentials against a wide spectrum of disease-causing bacterial strains such as *Salmonella typhimurium*, *Staphylococcus aureus*, *Bacillus cereus*, *Shigella dysenteria*, *Escherichia coli*, *Salmonella typhimurium*, *Listeria innocua* and *Listeria monocytogenes*. The volatile essential oil of *Commiphora africana* is known to inhibit the various pathological bacterial strains such as *Helicobacter pylori*, *Candida albicans*, *Escherichia coli* and *Staphylococcus aureus* [4].

Essential oils are generally added as food flavors and also act as anti-fungal and anti-bacterial additives. Macro-dilution technique is helpful in accessing the anti-microbial potentials of essential oils. Similarly, significant inhibition in mycelial growth of fungi can be observed on applying different concentrations of varied essential oils on an experimental basis. Essential oil extracted from thyme, tea tree, cinnamon and catnip exhibits maximum anti-microbial potentials. Some recent evidences have indicated that *in-vitro* applications of essential oil of *Thymus schimperii* Ronniger can act as a strong anti-bacterial agent against wide spectrum pathogenic fungal isolates such as *Microsporum gypseum*, *Beauveria bassiana*, *Aspergillus minutus*, *Aspergillus tubingensis*, *Verticillium* sp. and *Penicillium chrysogenum* [4].

Diabetes mellitus is a severe endocrinological metabolic disorder, rapidly spreading across the globe. Major symptoms of diabetes mellitus are high blood glucose levels as a consequence of inadequate secretion of pancreatic insulin or

CHAPTER 4

Management of Diabetes Mellitus by Natural Products: Glucagon-like Peptide 1 Perspective

Ojaskumar D. Agrawal^{1,2} and Yogesh A. Kulkarni^{1,*}

¹ Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L Mehta Road, Vile Parle (W), Mumbai – 400 056, India

² Vivekanand Education Society's College of Pharmacy, Chembur (E), University of Mumbai, Mumbai 400074, India

Abstract: Diabetes Mellitus (DM) has become a major and serious health problem worldwide. To overcome this lifestyle disease, natural products can be explored systematically. These natural products act on various targets and show their effect in diabetic conditions. Out of this, GLP-1 Receptor is one of the promising targets. Cells in the small intestine secrete Incretin hormones upon nutrient ingestion. Glucagon-like peptide-1 (GLP-1) is a primary incretin hormone in metabolism that has a potent antihyperglycemic effect. Insulin will release, in the presence of hyperglycemia, GLP-1 stimulates the pancreas to release insulin, stops glucagon release, gastric emptying slows down and increases satiety by acting on the hypothalamus. Storage of GLP-1 is mainly in secretory granules of L cells, in small intestinal distal portion and colon. When the cells are activated, this peptide is released into the main bloodstream. GLP-1 secreted mainly upon the ingestion of oral glucose or the ingestion of a mixed meal. Other factors like neurotransmitters and intestinal hormones also affect GLP-1 secretion from the intestine. Considering the above-mentioned parameters, regulation and control of GLP-1 are necessary as GLP-1 secretion is hampered in T2DM.

The present chapter focuses on scientific information about natural products specifically acting as GLP- 1 Receptor Agonist (GLP-1 RA).

Keywords: Diabetes Mellitus, GLP-1 Receptor Agonist, Herbal Medicine, Insulinotropic, Natural Products.

INTRODUCTION

The number of individuals suffering from diabetes has reached 425 million. International Diabetes Federation data shows that in 2045 there will be 629 million people affected with diabetes. At the global level, India is going to be one

* **Corresponding author Yogesh A. Kulkarni:** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L Mehta Road, Vile Parle (W), Mumbai – 400 056, India; E-mail: yogeshkulkarni101@yahoo.com

of the major countries having a large number of diabetic patients. Regular exercise and a healthy lifestyle can reduce the risk of this disease. The invention of a new drug molecule which is safer and better than the existing one, newer methodology and approach is need of an hour. All these invented drugs will help in reducing diabetes and its complications and as a result decrease in mortality and morbidity [1, 2].

Synthetic antidiabetic drugs have drawbacks like poor bioavailability, the too short or too long half-life, low therapeutic index, non – linear kinetics because of saturable clearance mechanism, on repeat, dosing increased clearance because of auto induction, multiple metabolites not covered by toxicity studies [1].

Considering the above points, there is utmost need to find out more efficacious, better and safer alternatives in the management of diabetes [2]. In recent years various natural products have been evaluated and proved for their beneficial effects in the management of diabetes.

In the ancient era, medicinal plants which are collected from the forest were only the basic source of drugs for all types of ailments. Hence more Weightage is given to these traditional and herbal drugs which can be used to treat all types of diseases. Thus medicinal natural products are playing a crucial role in the management of health care. Over twelve hundred medicinal plants have been identified and have been claimed as a remedy for diabetes and out of those, several hundred have been evaluated for the said treatment [3]. Several synthetic compounds have been discovered from medicinal plants like metformin, which was based on biguanide compound from plant *Galanga officinalis* [3]. Throughout the world, more than 400 plants, over 700 recipes and compounds have been broadly evaluated for T2D treatment [4]. In the human body, these natural products act on various targets and show their effects.

Glucagon-Like Peptide - 1

Upon oral glucose intake, gastrointestinal tract secretes incretin hormones [5]. These are gut peptides generally secreted after food intake and augment insulin secretion. Incretin hormones like Glucose-dependent insulintropic polypeptide and Glucagon-Like Peptide -1 are secreted by upper K cells and lower enteroendocrine L cells of gut respectively.

Also, GLP-1 has different and multiple effects on different organs. GLP-1 is responsible for decreasing apatite which is linked with food intake and weight loss. GLP-1 is synthesized from the posttranslational modification of proglucagon, by Prohormone Convertase 1 (PC1). It stimulates Glucose Stimulated Insulin Secretion (GSIS) when glucose and free fatty acids are taken

orally [6]. It has been reported that GLP-1 has insulinotropic action. High sugar intake results in increased GLP-1 secretion and ultimately in the stimulation of β -cells which secretes insulin. This proves that GLP-1 mimetics or its receptor agonists can be used for the management of diabetes [7].

Chemically, GLP-1 is available in two forms: GLP-1 (7–36) amide (80% of circulating GLP-1) and GLP-1 (7–37) amide. GLP-1 (1–36 amide) is predominantly secreted in the pancreas, whereas GLP-1 (1–37) is secreted in the ileum and hypothalamus [8 - 13].

Secretion of Incretin Hormones in Healthy Human Subjects

Carbohydrates like glucose and sucrose, starch; amino acids, triglycerides and proteins stimulate the secretion of GLP-1.

Proteins serve as a relatively weak stimulus for GLP-1 secretion. For this purpose, a minimum fixed rate of gastric emptying is required to have measurable secretion. Despite the distal location of secretory L cells in the gut, GLP-1 will be secreted immediately after ingestion of nutrients and meals [14].

Deacon and Holst identified that for degradation of GLP-1, dipeptidyl peptidase 4 (DPP-4) enzyme in plasma is responsible [15] and also showed that this degradation could be prevented by inhibiting enzyme DPP-4 [16]. GLP-1 has a very short half-life (<2 min) because of its speedy cleavage by Dipeptidyl peptidase-4 (DPP-4) [7]. Studies on pigs showed that practically it was possible to prevent degradation of GLP-1 by DPP-4 and this action showed a marked increase in insulin in response to glucose and GLP-1 [17].

GLP-1 affects levels of insulin and glucagon to decrease elevated blood sugar levels in two ways. First GLP-1 increases the body's natural insulin secretion in response to a meal and second GLP-1 lowers levels of the hormone glucagon after eating. Glucagon works opposite to insulin and raises blood sugar levels, so decreasing glucagon level helps to lower blood sugar. For insulin production, β -cell protection and β -cell proliferation, attenuating gastric emptying, reducing glucose secretion, decreasing appetite/weight, GLP 1 has a pivotal role [18, 19].

Various medicinal plants extracts have also reported increasing secretion of GLP-1. Natural products stimulate GLP-1 receptor on the enteroendocrine cells of GIT. As a result, depolarization of the enteroendocrine cell membrane by an increase in the level of intracellular calcium concentration and secretion of GLP-1 (Fig. 1).

CHAPTER 5**Terpenes and Terpenoids in Management of Diabetes & Cardiovascular Diseases****Kaveri M. Adki¹, Ankit P. Laddha¹, Manisha J. Oza^{1,2}, Anil Bhanudas Gaikwad³ and Yogesh A. Kulkarni^{1,*}**¹ Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai-400056, India² SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai 400056, India³ Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus Pilani- 333031, Rajasthan, India

Abstract: Diabetes mellitus is a chronic metabolic disorder and is one of the major leading causes of death worldwide. According to the World Health Organisation, the burden of diabetes has increased almost two-fold in 2014 compared to 1980 in low- and middle-income countries. Uncontrolled levels of glucose in the blood are because of improper insulin secretion or insulin action which is associated with abnormalities in metabolic, genetic and hemodynamic systems. The term cardiovascular disease is used for all types of disorders associated with heart and blood vessels. Many researchers are trying to develop new therapeutic approaches for the treatment of diabetes and cardiovascular disease. Herbal medicines are one of the oldest and alternative therapeutic treatment options for diabetes and hypertension. Around 1200 traditional medicinal plants have been used for their beneficial effects on diabetes. These plants are rich in alkaloids, glycosides, flavonoids, polyphenols and terpenoids. Terpenoids are a diverse category of cyclic compounds obtained naturally from the isoprene unit. Among all reported natural products, about 60% of compounds are from terpenoids. More than 40,000 terpenoids are isolated from secondary metabolites of plants. Most of them are of plant dietary origin. Plants produce terpenoids as a secondary metabolite. More than hundreds of new terpenoid structures are reported every year for their activity in many disease conditions like cancer, malaria, inflammation, and a variety of infectious diseases. Various reports have shown that terpenoids are beneficial in the treatment of diabetes and cardiovascular diseases. The chapter is focused on terpenoids and their role in the treatment and management of diabetes and cardiovascular diseases.

Keywords: Arjunolic acid, Cardiovascular diseases, Corosolic acid, Diabetes, Glycyrrhetic acid, Ginsenoside, Lupeol, Limonene, Pomolic acid, Terpenoids, Ursolic acid.

* **Corresponding author Yogesh A. Kulkarni:** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai-400056, India; E-mail: yogeshkulkarni101@yahoo.com

M. Eddouks (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

INTRODUCTION

Diabetes mellitus (DM) is a chronic endocrine disease with a severe impact on modern global health. Diabetes occurs either when the pancreas does not produce the required amount of insulin or when the body cannot use the insulin produced by the pancreas. Blood glucose levels are mainly monitored by insulin. Hyperglycemia is an effect of uncontrolled diabetes. Continuous hyperglycemia leads to damage to nerves and blood vessels. World health organization (WHO) has classified diabetes into six types as type 1, type 2, hybrid forms of diabetes, other specific types, unclassified diabetes and hyperglycemia first detected during pregnancy. Type 1 diabetes mainly occurs due to β -cell destruction. Type 1 diabetes is immune-mediated and there is an absolute deficiency of insulin. The onset of type 1 is common in children and adults. Type 2 diabetes is the most common. Type 2 diabetes mainly occurs due to insulin resistance and various degrees of β -cell destruction. Type 2 diabetes is associated with overweight and obesity. Hybrid forms of diabetes are subdivided into two categories as slowly evolving, immune-mediated diabetes of adults and ketosis-prone type 2 diabetes. Slowly evolving, immune-mediated diabetes of adults is similar to type 1 but mainly due to metabolic syndrome of glutamic acid decarboxylase autoantibody and ketosis-prone type 2 diabetes is due to ketosis and insulin deficiency. Other specific types of diabetes have again classified into seven subdivisions including Monogenic diabetes (single gene defects of β -cell function or insulin action), Diseases of the exocrine pancreas (any defect to pancreas like inflammation, trauma and tumor), Endocrine disorders (over secretion of hormones that are insulin antagonists), Drug- or chemical-induced (impairment of insulin secretion or action due to medicines and chemicals), Infection-related diabetes (associated with viruses having direct β -cell destruction property), Uncommon specific forms of immune-mediated diabetes and other genetic syndromes sometimes associated with diabetes (due to chromosomal and any genetic disorders). Unclassified diabetes in this category of diabetes does not fit in any above classification. Hyperglycaemia first detected during pregnancy is subdivided into two types as follows diabetes mellitus in pregnancy (type 1 or type 2 diabetes diagnosed for the first time during pregnancy) and gestational diabetes mellitus (hyperglycemia below the diagnostic thresholds for diabetes in pregnancy). Diagnosis criteria for diabetes have been updated by the WHO in 2019. The person is said to be diabetic if 2-hour post-load plasma glucose equal to or more than 11.1 mmol/L, fasting plasma glucose equal to or more than 7.0 mmol/L or HbA1c equal to or more than 48 mmol/mol. Criteria for a pregnant woman are with 1-hour post-load plasma glucose equal to or more than 10.0 mmol/L, 2-hour post-load plasma glucose 8.5–11.0 mmol/L or fasting plasma glucose 5.1–6.9 mmol/L [1]. It is estimated that around 422 million people living with diabetes in 2014 this prevalence almost doubled since 1980 in low- and middle-income countries. The WHO also reported

that 1.5 million deaths occurred due to diabetes and 2.2 million deaths occurred due to hyperglycemia in 2012 [2].

Cardiovascular Diseases (CVDs) are one of the leading causes of death in the world. CVDs include conditions like hypertension, angina (chest pain due to decreased blood flow to the heart), arrhythmia (irregular heartbeats), heart attack (blockage to the heart's blood vessel) and heart failure. According to the WHO, around 17.9 million people died from CVDs in 2018. Out of this, 85% of deaths are due to heart attack and heart failure. CVDs affect equally in men and women. It is estimated that 23.6 million people will die from CVDs by 2030 [3].

DM is responsible for the development of vascular diseases. The major risk factors include modern lifestyle, junk food, less physical activities, obesity, genetic factors, physical and mental stress [4].

Interconnection between Diabetes and Cardiovascular Diseases

Persistent hyperglycemia causes activation of molecular pathways like polyol, hexosamine, advanced glycation end products (AGEs) and protein kinase C (PKC), which may damage vital organs like brain, eyes, kidney and heart. Hyperglycemia alters cellular, sub-cellular and molecular mechanisms mainly by upregulating the pro-inflammatory biomarkers like interleukins, cytokines, transforming growth factor- β (TGF- β) and nuclear factor kappa B (NF- κ B) [5].

About 50% of diabetics, either type 1 or 2 have chances to develop CVDs. The prevalence of CVDs in diabetes may vary with age, sex, basal mass index, presence of kidney disease and others. Hyperglycemia may lead to impairment in systolic and diastolic functions of the heart in diabetic patients independent of the presence of coronary heart disease [6]. Clinical and epidemiologic data from the last two decades have shown that the prevalence of hypertension and heart failure in diabetes is very high. It is predicted that the rate of mortality and morbidity is around 27 per 1000 diabetic patients per year compared to those without diabetes [7, 8].

Scientists are working to understand the exact mechanism of CVDs in diabetics. The literature revealed that continuous functional and metabolic alterations lead to prompt irreversible changes in heart of diabetics. The altered metabolism is associated with increased oxygen consumption in myocardial tissue and increased concentrations of free fatty acids (FFA) in the serum. The excess FFA uptake and hyperglycemia leads to dysfunction of mitochondria present in the heart. This leads to increased calcium sensitivity in cardiomyocyte and abnormality in contractile and regulatory protein expressions in diabetics. It is also reported that reduced activity of calcium pump and the rate of calcium removal of sarcoplasmic

Antidiabetic and Antihypertensive Medicinal Plants of Asia: Active Ingredients, Safety, Pharmacology, and Traditional Uses

Subrata Das¹, Anupam Das Talukdar¹, Manabendra Dutta Choudhury¹ and Sanjoy Singh Ningthoujam^{2,*}

¹ Department of Life Science and Bioinformatics, Assam University, Silchar, India

² Department of Botany, Ghanapriya Women's College, Dhanamanjuri University, Imphal, India

Abstract: Diabetes mellitus and hypertension are the two most common diseases in modern civilized countries. It is suggested that hypertension is more likely to be associated with type II diabetes as the patient acquires both diseases at old age. Though several therapeutic approaches were developed to treat the complications, plant-based therapeutics remains one of the most promising approaches. Moreover, traditional medicine remains as a primary health care system in the resource constraint societies. The use of medicinal plants for therapeutic uses has a long tradition in Asia in the form of Ayurveda, Traditional Chinese Medicine, Unani, Jamu, *etc.* In recent years, the scientific community has focused on natural products derived from ethnomedicinal plants for their wide therapeutic potentials, including diabetes mellitus and hypertension. Phenformin, metformin, repaglinide (Prandin), nateglinide (Starlix), pioglitazone, rosiglitazone, acarbose, miglitol are some of the antidiabetic marketed drugs of plant origin. Lignans, cinnamaldehyde, and protodioscin are newly isolated anti-diabetic drugs from plant sources. This chapter attempts to highlight the medicinal plants of Asia used for antidiabetic and antihypertensive purposes with regard to their phytochemical potentials, biosafety, and scientific evaluation of their traditional uses.

Keywords: Antidiabetic, Antihypertensive, Asia, Medicinal plants, Plant-based therapeutics, Traditional medicine.

INTRODUCTION

Diabetes

Diabetes mellitus (DM) is an important chronic disease triggered by an inappropriate balance of glucose homeostasis [1]. DM is a severe chronic

* Corresponding author Sanjoy Singh Ningthoujam: Department of Botany, Ghanapriya Women's College, Dhanamanjuri University, Imphal, India; Email: ningthouja@hotmail.com

metabolic disorder that affects health, quality of life, and life expectancy of patients, as well as the health care system. According to the World Health Organization (WHO), 171 million people worldwide suffer from diabetes; this number is expected to be more than double by 2030 and around 3.2 million deaths every year are attributable due to diabetes; six deaths every single minute [2]. Reports of the WHO showed that the diabetes epidemic is more pronounced in India than in other parts of the world. 32 million people had diabetes in the year 2000 [3]. The International Diabetes Federation (IDF) estimates the total number of diabetic condition subjects to be around 40.9 million in India, and this is further set to increase to 69.9 million by the year 2025. Reports of WHO have also shown that non-insulin-dependent diabetes mellitus (NIDDM) and its complications are increasing in sub-Saharan Africa, and the incidence of the disease is growing annually [4]. Diabetes is the most heterogeneous challenging disease. It can merely be categorized into type 1 diabetes mellitus and type 2 diabetes mellitus [5]. The distinction between type 1 and type 2 diabetes mellitus solely depends on the clinical appearance, such as age at disease commencement, the incidence of ketosis, and insulin dependence. Type 1 diabetes mellitus, occurring mainly in childhood or young adulthood, is earmarked by T cell-mediated autoimmune destruction of beta cells, absolute insulin dependence, and the need for insulin treatment. Type 2 diabetes mellitus, mainly occurring in adulthood, is the outcome of insulin resistance and relative insulin deficit [6]. Diabetes or hyperglycaemic condition can be caused through the inhibition of key enzymes α -glucosidase and α -amylase for starch digestion. Drugs that are in use now, such as miglitol, acarbose, nojirimycin, voglibose, and 1-deoxynojirimycin possess unbearable toxicity, which triggers the finding of natural inhibitors of glucosidase and amylase from the plant sources [7].

Hypertension

High blood pressure or hypertension (HTN) is a common cardiovascular complication, which has become a global problem. 15–20% of all adults with ailments, such as arteriosclerosis, stroke, myocardial infarction, and end-stage renal diseases are due to hypertension [8]. It is stated that NIDDM is the result of prolonged hypertension complications. These two diseases (NIDDM and hypertension) are interconnected metabolic syndromes. Prolonged persistent hypertension serves as a risk factor for stroke and chronic renal failure [9]. Angiotensin-I converting enzyme (ACE) is a key enzyme that controls the regulation of blood pressure. It translates angiotensin I to angiotensin II, which is an effective vasoconstrictor. The inhibition of ACE activity provides an antihypertensive potential by simultaneously lowering blood pressure in non-diabetic and diabetic patients [10]. Lisinopril, captopril, and enalapril are drugs currently used as ACE inhibitors and have been reported to be harmless and

effective. Search for non-toxic ACE inhibitors provides a direction towards the use of dietary phenolic phytochemicals and is shown to have promising effectiveness [11]. In recent decades, the consumption of vegetables for antihypertensive and antidiabetic phytochemicals has attracted growing interest. Many experimental and epidemiological studies have reliably verified a positive connection between the intake of these natural foodstuffs and reduced risks of several degenerative diseases, including NIDDM [7]. Phytochemical rich foods consist of several antioxidants, especially antioxidative vitamins, including ascorbic acid (vitamin C), α -tocopherol (vitamin E), and β -carotene (provitamin A), which may provide a defensive role against these complications. Studies indicated that polyphenolic compounds are the main phytochemicals, with greater antioxidant properties found in plants [7]. Phenolics in plant products are present in free or aglycone and bound or glycoside forms [12]. The free phenolics are more easily absorbed and thus provide helpful bioactivities in food assimilation. However, the number of different bound phenolics are assimilated and absorbed at several sites of the gastrointestinal tract where they do their duty for the benefit of health [7]. Type 2 diabetes mellitus and hypertension are two highly predominant diseases among the aged that make them vulnerable to vascular disease. The occurrence of type 2 diabetes in the age group of 65 years and older is approximately between 15% and 25% [13], whereas, for hypertension, the range is between 50% and 70% [14].

Diabetes and Hypertension

Diabetes and hypertension are interconnected in most diabetic people and the prevalence of getting hypertension is two folds that of the non-diabetic person [15, 16]. Prolonged diabetes damages arteries and causes a condition called atherosclerosis. This condition leads to the development of high blood pressure along with other circulatory hindrance. In type 2 diabetes due to insulin resistance, hyperinsulinemia develops, which regulates the Angiotensin-I converting enzyme to convert Angiotensin-I to Angiotensin-II. As a result, Angiotensin-II regulates the vasoconstriction and develops hypertension in diabetic condition [10]. Below mentioned Fig. (1) demonstrates the connection link between diabetes and hypertension.

Chrysophyllum Cainito L.

A. Sánchez-Recillas^{1,*}, L. Cerón-Romero², R. Ortiz-Andrade¹ and J.C. Sánchez-Salgado³

¹ Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Calle 43 No. 613 x Calle 90 Col. Inalámbrica. C.P. 97069, Mérida, Yucatán, Mexico

² División Académica de Ciencias Básicas, Universidad Juárez Autónoma de Tabasco, Carretera Cunduacán-Jalpa KM. 1. Col. La Esmeralda C.P. 86690, Cunduacán, Tabasco, Mexico

³ Instituto de Inmunología y Enfermedades Complejas. Av. San Jerónimo 819, 106-D, San Jerónimo Lídice, Magdalena Contreras, C.P.10200, Mexico City, Mexico

Abstract: *Chrysophyllum cainito* L. is part of the family Sapotaceae and native to the Greater Antilles and the West Indies. This specie is a medicinal plant used around the world by many cultures, commonly known as “star apple” or “caimito”. Some studies have reported that *C. cainito* possesses many pharmacological properties as antidiabetic, anti-hypersensitivity, antihypertensive, anti-inflammatory, antimicrobial, antinociceptive, antioxidant, gastroprotective and immunosuppressive. Also, phytochemical evidence has revealed that the main secondary metabolites in *C. cainito* are alkaloids, tannins, flavonoids, phenols, sterols, coumarins and triterpenes which are responsible for their pharmacological benefits. *In vitro* and *in vivo* toxicology studies have suggested human consumption of *Chrysophyllum cainito* leaves as safe. This chapter includes scientific information of pharmacology, toxicology and phytochemistry of *C. cainito* seeds, leaves, and fruits with the purpose to contribute valuable scientific information to future research in drug development based on *C. cainito* as a source of raw material.

Keywords: Antidiabetic, Anti-inflammatory, Antimicrobial, Antinociceptive, Antioxidant, *Chrysophyllum cainito* L., Immunosuppressive, Medicinal use, Pharmacology Phytochemicals, Toxicity.

INTRODUCTION

Chrysophyllum cainito is part of the family Sapotaceae and native to the Greater Antilles and the West Indies. It is spread in the lowlands of Central America and now is very common and cultivated throughout the tropics, including Southeast Asia [1]. The fruit is named as star apple, cainito, caimito or cayumito, and its fla-

* Corresponding author Sánchez-Recillas: Área de Farmacología Experimental, Facultad de Química, Universidad Autónoma de Yucatán (UADY) - Calle 43 No. 613 x Calle 90 Col. Inalámbrica. C.P. 97069. Mérida, Yucatán, México; E-mail: amanda.sanchez@correo.uady.mx

vor is a mixture between green grapes and litchi. This specie is used in folk medicine for the treatment of inflammation such as laryngitis, pneumonia, rheumatoid arthritis, and diabetes mellitus [2]. The chemical analysis has described several secondary metabolites including alkaloids, flavonoids, phenols, sterols, and triterpenes which are well known to have pharmacology properties. The biological activity of *C. cainito* has been also investigated comprehensively [1 - 3], and in this chapter, we assemble the information of *C. cainito* describing the ethnomedical, chemical, pharmacological, and toxicological properties providing wide scientific evidence of its medicinal benefits and worthiness as a source of new chemical agents in the drug discovery process.

SYNONYMS

C. cainito L is also known by many other synonyms around the world. The most common synonyms are *Cainito pomiferum* Tusac, *Chrysophyllum bicolor* Poir, *Chrysophyllum bonplandii* Klotzsch ex Miq, *Chrysophyllum monopyrenum* Sw, *Chrysophyllum sericeum* Salisb, *Cynodendron bicolor* (Poir.) Baehni [1], and *Achras cainito* Ruiz & Pavon [2].

BOTANICAL FEATURES [3]

Kingdom: Plantae
Subkingdom: Viridiplantae
Division: Tracheophyta
Class: Magnoliopsida
Superorder: Asteranae
Order: Ericales
Family: Sapotaceae
Genus: *Chrysophyllum* L.
Species: *C. cainito* L.



VERNACULAR NAMES

Chrysophyllum cainito is most commonly known as “caimito” or “cayumito”. However, many names are reported of this specie (Table 1).

C. cainito is an evergreen tree with alternate oblong-lanceolate leaves and flowers blooming from May to October, which are small, white to greenish in color. A green to purple fruit with approximately 5-8 cm in diameter is characterized by fleshy and edible pericarp. The epicarp or peel is hard on the external tissues and soft on the internal ones [8]. The fructification is mixed; the first fruits appear in July and are prolonged until the following year [9]. *C. cainito* is propagated by

seed and it can germinate to about 60% by mechanical scarification [10 - 13].

Table 1. Reported vernacular names for *Chrysophyllum cainito* L. worldwide.

Geographical Region	Vernacular Name	Reference
AMERICA		
<i>North America</i>		
Mexico	Caimito or Cayumito	[1]
Oaxaca	Canela	[4]
Chiapas	Chicle de monte	[4]
San Luis Potosi	Isi, ocotlan	[4]
United States		
Florida (southern)	Star apple	[6]
<i>Caribbean</i>	Star apple (overall)	[5]
Haiti	Pied caimite or caimitier a feuilles d'or	[2]
French West Indies	Pomme surette, or buis	[2]
Virgin Islands	Cainit	[2]
Trinidad and Tobago	Caimite or kaimit	[2]
Barbados	Star-plum	[2]
<i>Central America</i>	Star apple (overall)	[5]
Belize	Damsel	[2]
El Salvador	Guayabillo	[2]
Nicaragua (eastern)	Apil	[7]
<i>South America</i>	Star apple (overall)	[5]
Colombia	Caimo, caimo morado (purple variety) or caimito madura verde (green variety)	[2]
Bolivia	Caimitero, or murucuja	[2]
Surinam	Sterappel, apra or goudblad boom	[2]
French Guiana	Macoucou	[2]
Argentina	Aguay or olivoa	[2]
EUROPE		
Spain	Caimito or Estrella	[2]
Portugal	Cainito orajara	[2]
France	Caimite or caimitier	[2]
ASIA		
Singapore	Chicle durian	[2]

SUBJECT INDEX

A

- ABTS assays 199
 Acid 47, 63, 78, 75, 99, 100, 101, 102, 132,
 135, 146, 155, 168, 170, 171, 175, 174,
 176, 177, 178, 194, 195, 197, 198
 acacic 170
 Angelic 132
 aristolochic 176
 ascorbic 146, 168, 174, 195
 chlorogenic 99, 100
 Cubebic 78
 deoxyribonucleic 63
 echinocystic 170
 ferulic 195
 gallic 171, 177, 194, 198
 hexacosanoic 171
 loganic 101, 102
 oleanolic 75, 135, 170, 172, 176, 178
 succinic 177
 uric 47
 Actin cytoskeletons 18, 20
 Activation 10, 16, 17, 18, 19, 20, 21, 22, 23,
 27, 28, 49, 110, 129, 130, 146, 148, 152,
 153
 of extracellular signal-regulated protein
 kinase 27
 mediated inflammatory 23
 metabolic 49
 serine/threonine kinase 28
 Activity 20, 21, 46, 48, 49, 51, 63, 69, 70, 73,
 74, 81, 82, 84, 99, 103, 105, 106, 133,
 142, 143, 144, 148, 149, 153, 154, 155,
 156, 172, 173, 175, 176, 179, 200, 201,
 203, 205
 analgesic 175
 antiatherogenic 148
 antiatherosclerosis 48
 anti-atherosclerotic 155
 antibacterial 63
 anticholinesterase 144
 antidepressant 133
 anti-diabetic 69, 70, 73, 74, 103
 antiglycation 143
 anti-hyperglycemic 173
 anti-hypersensitivity 201
 antihypertensive 176, 203
 anti-hypertensive 81
 anti-inflammatory 46, 155, 175, 201
 antimutagenic 49
 antiproliferative 205
 hemostasis 156
 hepatoprotective 51
 hypertensive 179
 hypocholesterolemic 142
 hypoglycaemic 106
 hypolipidemic 149
 hypotensive 156
 Adiponectin 10
 Adipose tissue 4, 5, 22
 dysfunction 4, 5
 lipolysis 22
 Agent 47, 63, 146, 148, 156, 180
 cardioprotective 146, 148
 non-toxic therapeutic 180
 strong anti-bacterial 63
 Ajwa date 42, 51
 Ajwain 177
 Alcoholic extract 70, 74
 Alcohols 40, 62, 79, 135
 arteannuic 79
 Alkaline phosphatase 139, 142
 Alkaloids 38, 41, 48, 50, 79, 169, 170, 171,
 189, 190, 192
 isoquinoline 171
Allium 83, 172, 173, 179
 cepa 82, 172, 179
 sativum 83, 173, 179
 Alpha-adrenergic receptor antagonist 204
 Alzheimer's disease 47, 48, 49
 curcumin 47
 AMK-dependent mechanism 20
 Amyloid angiopathy 68
Anchusa officinalis 69, 77
 Ancient Chinese methods 67
 Angiogenesis 141
Annona 173, 175, 199, 202

muricata 175, 199, 202
squamosa 173
 Antiapoptotic activity 27
 Anti-bacterial additives 63
 Antidiabetic 38, 48, 98 130, 136, 137, 143,
 148, 151, 152, 153, 154, 166, 168, 170,
 171, 172, 173, 175, 176, 179, 189
 agent 38, 148, 153, 154
 effect 48, 98
 phytochemicals 168
 Anti-hypertensive 61, 69, 77, 79, 83
 effects of garlic 83
 plants 61, 69, 77, 79
 Anti-inflammatory 51, 170, 200
 agents 51, 170
 effect 200
 Antilipolytic effects 8
 Antioxidant properties 168, 199
 Anti-oxidants 63
 natural 63
 synthetic 63
 Apoptosis 9, 11, 46, 152
 curcumin-induced 46
 induction 46
 stress-induced 152
 Appetite suppressant 106
 Arjunolic acid in cardiovascular diseases 146
 Arthritis 48, 190, 199
 rheumatoid 190, 199
Aspergillus 63
minutus 63
tubingensis 63
 Assays 74, 112, 144, 146, 151, 198, 200, 205
 bovine brain peroxidation 144
 enzyme-linked immune sorbent 151
 enzyme-linked immunosorbent 112
 ferric reducing/antioxidant power 146
 glucose oxidase 74
 Atherosclerosis 48, 155, 168, 175
 lesions 155
 ATP-independent facilitative diffusion 18
 ATP-sensitive potassium 27, 115
 channel 115
 Autoimmune disorder 2
Avena sativa 83, 176
 Ayurveda for oxidative stress 145
 Ayurvedic system 42

B

Bacillus cereus 63
Bambusa arundinacea acts 70
 Blood glucose 1, 7, 14, 41, 43, 48, 74, 106,
 115, 140, 144, 149, 152
 concentration 1, 7, 106
 reduced 48
 reduced fasting 140
 Bovine serum albumin (BSA) 144

C

Cainito 189, 197, 201, 202, 203, 205
 fruits 197, 201, 202, 203
 juice 203
 methanol extract 201
 seeds 189, 205
 Calcium 80, 82, 129
 channel blockade effects 80
 influx 82
 pump 129
Camellia sinensis 112, 139, 177
Candida albicans 63
 Carbohydrates 40, 66, 70, 72, 97, 113, 170
 dietary 113
 Carboxylic acids 135
 Carcinogenesis 46
 Carcinogenicity 46
 Cardiac 50, 61, 83, 147
 arrest 61, 83
 fibroblast 147
 glycosides 50
 Cardiomyocyte 129
 Cardioprotective activity 146, 147, 148, 151,
 156
 of ursolic acid 148
 Cardiovascular 26, 81, 127, 129, 139, 141,
 144, 146, 148, 149, 152, 154, 156, 175,
 176
 diseases 127, 129, 139, 141, 144, 146, 148,
 149, 152, 154, 156, 175, 176
 hypertrophy 81
 injury 152
 protective activity 156
 stability 26
Centaurea bruguierana 179
 Cholesterol synthesis 19
 Chronic diseases 38, 144, 206

non-communicable 206
 Ciocalteu colorimetric method 198
 Constipation 171
 Corosolic acid 127, 152, 153, 154, 155
 vasodilatory activity 155
 vasodilatory effect of 155
 Corosolic acid in cardiovascular diseases 154
 Corosolic acid in diabetes 153
 Cumin 61, 71, 78, 84
 alcohol 78
 black 61, 84
 Curcumin 42, 43, 44, 45, 46, 47, 108, 109
 cancer cells 47
 cystic fibrosis 47
 dietary 44, 45
 inhibition 46
 Cushing's syndrome 3
 Cytokines 4, 8, 9, 12, 21, 23, 46, 68, 129, 141, 201
 proinflammatory 68
 proinflammatory-mediated 8
 signaling 21
 Cytoplasmic fluid 62

D

Diabetes 2, 3, 127, 128, 129, 130, 139, 153, 168, 169
 and cardiovascular diseases 129, 139
 and hypertension 127, 130, 168, 169
 demographic and geographic outline of 2, 3
 gestational 3
 immune-mediated 128
 -related enzymatic activities 153
 Diabetes mellitus 1, 52, 61, 128, 166, 167, 168
 and hypertension 61, 66, 166, 168
 dependent 1
 gestational 128
 non-insulin-dependent 167
 therapy 52
 Diabetic 38, 39, 144
 cardiomyopathy 39
 complications 38, 144
 Diet 40, 82, 142
 high-cholesterol 142
 high fructose 82
 low total fats 40
 Dietary 98, 176, 177
 fibre 98
 oat fiber 177

 therapy, effective 176
 Diseases 26, 27, 28, 39, 42, 50, 53, 64, 66, 68, 80, 85, 96, 127, 128, 129, 130, 148, 155, 166, 167
 atherosclerosis-related 155
 cerebrovascular 39
 chronic endocrine 128
 coronary artery 39
 coronary heart 129
 diabetes-induced cardiac 148
 heterogeneous 66
 infectious 127
 kidney 64, 129
 renal 130, 167
 respiratory 42
 treatment of diabetes and cardiovascular 127
 DNA 17, 63, 73, 143
 binding properties 17
 breakage 73
 damage 143
 Drosophila son-of-sevenless protein 17
 Drugs 24, 41, 61, 69, 96, 108, 110, 116, 128, 130, 153, 156, 166, 167, 180, 206
 developing anti-diabetic 110
 herbal 96
 isolated anti-diabetic 166
 produced modern 61
 synthetic 69, 130, 156
 therapeutic 24, 180
 Dysfunction 7, 11, 129, 130
 cardiac diastolic 130
 cellular 11
 myocardial 130

E

Effect of 99, 101, 104, 107, 109, 110, 113
 Berberis vulgaris on glucose level 110
 butyrate on glucose level 113
 Cichorium intybus on glucose level 104
 Cinnamomum zeylanicum on glucose level 104
 Curcuma longa on glucose level 109
 Mangifera indica on glucose level 107
 Momordica charantia on glucose level 101
 Endothelial 46, 47, 83, 84
 dysfunction 47
 dysfunctioning 84
 injury 83
 tissue factors 46

- Enzymes 9, 70, 71, 97, 108, 137, 151
 carbohydrates metabolizing 71
 genes encoding 137
 inositol-requiring 9
 phosphoenolpyruvate carboxykinase 151
 Extracellular signal-regulated protein kinase
 27
- F**
- Fasting plasma glucose 128
 Fats 1, 6, 8, 15, 67, 77, 111, 155, 198
 dietary 77
 healthy monounsaturated 111
 intra-abdominal 8
 mesenteric 8
 Fatty acids 8, 12, 19, 21, 63, 67, 113
 elevated free 12
 predominant Short-chain 113
 Fatty streaks transformations 83
 Fenugreek seeds 52, 72
 Fibre intake 107
 wheat 107
 Fibrinoid necrosis 68
 Flavonoids 41, 48, 50, 51, 76, 78, 79, 169,
 170, 172, 174, 177, 178, 189, 190, 192
 polyphenolic 174
 Free fatty acids (FFAs) 8, 9, 11, 12, 14, 22,
 71, 76, 129, 149, 154
 Free radical(s) 40, 63, 146, 148
 reactions 63
 scavenging activities 63, 146, 148
 production 40
- G**
- G - protein-coupled receptor (GPCR) 102
 Gastric 8, 25, 26, 111, 204
 inhibitory polypeptide (GIP) 8, 25, 26, 111
 injury 204
 mucosa 204
 Gastroenteritis 176
 Gastrointestinal 96, 114, 168
 digests 114
 tract 96, 168
 Genes 2, 3, 6, 12, 18, 26, 27, 28, 29, 142
 obesity-associated 28
 susceptible 2
 Genetic 3, 12, 23, 28, 128
 lipodystrophy 3
 mutations 12, 23, 28
 syndromes 128
 Genome wide association studies (GWAS) 26
 Genome-wide linkage methods 6
 Ginsenosides in cardiovascular diseases 152
 Glial cells 46
 Glucagon 7, 8, 25, 26, 67, 97, 108, 114, 151
 hormone 97
 release 114
 secretion 8, 114
 suppression 25
 Glucocorticoids 3, 13, 28
 Gluconeogenesis 4, 7, 10, 13, 14, 19, 24, 75,
 76, 151
 hepatic 4, 7, 10, 24
 Glucose 1, 13, 14, 15, 24, 40, 41, 42, 47, 48,
 52, 67, 70, 75, 96, 97, 98, 100, 106, 110,
 114, 116, 139, 166
 cytosolic 67
 decreased 139
 -dependent insulinotropic polypeptide 96
 homeostasis 13, 98, 110, 116, 166
 intolerance, reduced 116
 stimulated insulin secretion (GSIS) 96
 Glucose metabolism 20, 24, 48, 75, 111, 147
 reabsorption of 24
 serum 48, 75
 Glucose absorption 76, 148
 decreased insulin-stimulated 76
 reduced 148
 Glucose transport 4, 8, 14, 17, 18, 20, 21, 23
 impaired 4
 regulates the 18
 system 8, 21
 Glucose uptake 1, 6, 11, 13, 14, 15, 19, 20, 25,
 99, 100, 140, 147, 153, 156, 201
 activity 156
 impaired insulin-mediated 6
 impaired insulin-stimulated 25
 insulin-stimulated 20
 stimulation 201
 Glucosidase 167
 GLUT4 storage vesicles (GSVs) 18
 Glutamate pyruvate transaminase 48
 Glutathione 44, 47, 71, 146
 depletion, preventing 47
 expression 44
 hydroxylase level 146

- reductase 146
 - Glutathione peroxidase 143, 146, 152
 - activities 143
 - enzyme activities 143
 - Glycogenesis 67
 - Glycogenolysis 14
 - Glycogen 17, 18 19, 20
 - synthase 17, 20
 - synthesis 17, 18, 19
 - Glycolysis 14, 67, 76, 110, 154
 - Glycoprotein 27
 - Glycosides 41, 78, 79, 127, 169, 170, 205
 - cyanogenic 205
 - Glycosylated hemoglobin levels 43, 139
 - Glycosylates hemoglobin 140
 - Glycyrrhethinic acid 127, 149, 150, 151
 - acts on cardiac tissue 150
 - cardioprotective activity of 150, 151
 - in cardiovascular diseases 149
 - Glycyrrhethinic acid in diabetes 149
 - Grape-seed procyanidin extract (GSPE) 111
 - Growth 9, 17, 19, 28, 46, 63, 129, 131, 137
 - cellular 28
 - mycelial 63
 - transforming 129
 - GTPase-activating protein 20
 - Gut 96, 103, 113
 - lumen 113
 - microbiota 103
 - peptides 96
- H**
- Haemoglobin 48 75
 - glycosylated 48
 - Heart 64, 65, 85, 129
 - attack 65, 85, 129
 - stroke 64
 - Heartbeats, irregular 129
 - Heart failure 80, 129, 130
 - congestive 80
 - Helicobacter pylori* 63
 - Hemodynamic systems 127
 - Hepatic 13, 22, 25
 - de novo* lipogenesis 22
 - glucose production (HGP) 13, 25
 - Hepatocyte 6, 40
 - necrosis 40
 - nuclear factor 6
 - Hepatoprotective action 47
 - Herbal medicine 41, 102
 - therapeutic 102
 - and diabetes mellitus 41
 - High 48, 64, 65, 68, 72, 79, 81, 85, 150, 152, 167, 168, 176, 201
 - blood pressure 64, 65, 68, 79, 81, 85, 167, 168, 176
 - density lipoprotein (HDL) 48, 72, 150, 152, 201
 - Homeostasis 11, 25, 98, 148
 - lipid 148
 - metabolic 25
 - Hormones 1, 9, 13, 28, 67, 115, 128, 131, 137
 - anabolic peptide 1, 13, 28
 - glucagonotropic 115
 - pancreatic 67
 - Human renal cancer cells 46
 - Hypercholesterolemia 176, 179
 - Hyperglycemia 4, 7, 8, 12, 21, 23, 25, 38, 39, 40, 66, 67, 69, 128, 129, 130, 141, 146
 - chronic 4, 69
 - fasting 5, 141
 - reduced 146
 - Hyperinsulinemia 4, 12, 22, 23, 154, 168
 - compensatory 4
 - euglycemic 4
 - hyperglycemic 4
 - Hyperlipidemia 47, 71, 154
 - Hypersensitivity 200
 - Hypertension 80, 144, 1 48
 - genetic 148
 - intense 80
 - monocrotaline-induced pulmonary 144
 - reduced monocrotaline-induced 144
 - Hypertrophy-associated cardiac fibrosis 147
 - Hypoglycemic activity 41, 44, 47, 49, 50, 51, 52, 74, 148, 173
 - of *Gymnema sylvestre* 47
 - of *Piper nigrum* 49
 - of *Sesamum indicum* 50
- I**
- Impaired 11, 12
 - glucose tolerance (IGT) 11
 - insulin action and hyperglycemia 12
 - Inflammation 4, 8, 12, 51, 127, 128, 154, 155, 176, 179, 190, 199
 - biological defense mechanism 51
 - Inflammatory 4, 46, 47, 201

cytokines 46
 fragments 47
 hypothesis 4
 mediator 46
 pains 201
 Inhibition 9, 11, 12, 13, 15, 17, 19, 46, 81, 82,
 106, 110, 145, 146, 149, 167
 enzyme 81, 106
 glycogenolysis 15
 Insulin 1, 2, 4, 8, 12, 13, 14, 15, 16, 17, 19,
 20, 21, 22, 23, 24, 27, 28, 39, 40, 63, 67,
 76, 97, 110, 115, 128, 153
 deficiency 128
 dependent diabetes mellitus (IDDM) 1
 endogenous 4
 increased blood 110
 pancreatic 63
 receptor substrate (IRSs) 12, 13, 15, 16, 17,
 22, 23, 39
 secreted 8
 secretes 97
 Insulin resistance 1, 2, 4, 5, 6, 7, 8, 10, 11, 12,
 20, 23, 25, 28, 76
 hepatic 5
 mediated 12
 peripheral 4
 Insulin sensitivity 4, 24, 110, 148
 enhancing 110
 reduced 4
 Insulin signaling 4, 5, 6, 9, 12, 13, 14, 15, 19,
 20, 21, 22, 23, 28
 disrupts 21
 hepatic 23
 pathways 19
 reduced 5
 system 28

L

Lipid 21, 25, 45, 63, 149, 200
 peroxidation level 45
 Phosphatases Lipid 21
 profile 25, 149, 200
 unsaturated 63
 Lipid metabolism 14, 40, 103, 155
 abnormal 155
 Lipid peroxidation 40, 44, 45, 47, 71, 143
 by-products level 143
 decreased 45
 increased 40

Lipolysis 11, 14, 15, 25
 increased visceral 11
 Lipoperoxidation 144
 Lipoprotein lipase activity 8
 Lipotoxicity 8, 12, 23, 28
 Liquid chromatography 139
 Liver 3, 4, 5, 6, 10, 11, 13, 14, 15, 19, 20, 21,
 22, 24, 45, 48, 71, 143, 200
 cholesterol 71
 enzymes 45, 143
 glycogen 48
 Liver disease 45, 176, 179
 non-alcoholic 176, 179

M

Macroangiopathy 39
 Macro-dilution technique 63
 Macrophages 4, 9, 46, 133, 200
 human monocytic 46
 peritoneal murine 200
 proinflammatory 9
 MAP kinase 17, 22
 cascade 17
 kinase 17
 pathway 17
 phosphorylates Elk-1and 17
 translocates 17
Marrubium vulgare 179
 Mass spectroscopy 139, 143
 Medicinal plants 42, 43, 127
 chemical constituents of 42, 43
 traditional 127
 Medicines 38, 42, 69, 70, 76, 77, 83, 86, 106,
 128, 130, 132, 166, 170, 173, 176, 177,
 190, 199
 dysentery 199
 effective 70
 febrifuge 199
 folk 101, 190, 199
 natural 76
 synthetic 69, 77, 130
 traditional 132, 166, 170, 176, 177
 Mediterranean diet 172
 Melatonin receptor 27
 Membrane glycoprotein 28
 Metabolic 1, 12, 17, 22, 24, 38, 52, 63, 64, 66,
 127, 128, 167
 complications 38, 64
 disorder 1, 63, 66, 167

- chronic 127
 dysregulation 12
 effects 22, 24
 pathway 17
 profile 52
 syndrome 128
 Metabolism 5, 8, 14, 19, 20, 28, 64, 95
 abnormal 8
 carbohydrate 14
 cholesterol 64
 fatty acid 5
 Metaregression analysis 130
Methanocaldococcus jannaschii 138
 Microglial cells 46
Microsporium gypseum 63
 Mimosaceae family 170
 Mitogen-activated protein kinases (MAPK)
 39, 46, 146
 Multinucleated myoblast cells 150
 Muscle cells 82, 99, 151, 156
 human skeletal 99
 smooth 151
 vascular smooth 82
 Mutations 3, 6, 12, 15, 28
 inhibitory 15
 melanocortin receptor 3
 Myocardial 64, 129 130, 145, 149, 167
 infarction 64, 130, 167
 inflammatory injury, reducing 149
 necrosis 145
 tissue 129
- N**
- Nervous system 64, 65, 84
 autonomic 64
 Nervous tension 65
 Non-insulin dependent diabetes mellitus
 (NIDDM) 1, 167, 168
- O**
- Obesity 2, 3, 5, 7, 8, 9, 10, 11, 22, 28, 128,
 129
 genetic 3
 visceral 5
 Oxidative damage 44
 hepatic 44
 Oxidative stress 38, 40, 45, 48, 75, 81, 110,
 116, 144, 145, 146, 154, 155
 induced 45, 146
 markers, inhibited 154
 -related biomarkers 146
- P**
- Pathways 1, 9, 10, 13, 16, 17, 19, 23, 28, 44,
 46, 102, 136, 137, 138
 biosynthetic 137
 glucosidase α amylase 44
 insulin signal transduction 16
 intracellular metabolic 13, 28
 metabolic intracellular 1
 mitochondrial 46
 mitogenic 17, 19
 pentose phosphate 9
 shikimic acid 138
Penicillium chrysogenum 63
 Plasma 2, 51, 71, 97, 113, 139, 140, 148, 149
 cholesterol 71
 fibrinogen 51
 glucagon 2
 jugular vein 113
 Plasma glucose 48, 103 115, 149
 decreased fasting 103
 Pleiotropic effects 13, 25, 26
 Polar leafy extracts of henna 74
 Polycystic ovary disease 3
 Protein(s) 9, 10, 12, 14, 15, 16, 17, 20, 21, 27,
 28, 47, 63, 66, 97, 98, 114, 115, 151
 enzymatic 16
 expression analysis 151
 fraction 114
 hydrolysis 115
 metabolism 14
 mitochondrial 12
 oxidation 47
 -protein interactions 28
 Protein glycation 143, 144
 inhibited 143
 Protein kinase 9, 14, 20, 21, 22, 27, 39, 129,
 146
 B (PKB) 39
 calmodulin-dependent 27
 mitogen-activated 39, 146
 serine/threonine 9
 Protein phosphatase 17, 20, 21
 glycogen-associated 17

R

Reduction 10, 12, 14, 15, 22, 25, 50, 52, 72, 74, 76, 77, 99, 106, 142, 143, 144
 intestinal 106
 of intestinal glucose absorption 99
 Renal 45, 65
 infections 65
 oxidative damage 45
 Renin-angiotensin-aldosterone system (RAAS) 130
 Renovascular hypertension 80
 Retinoid X receptor (RXR) 6
 Retinopathy 39, 66

S

Salt induced hypertensive (SIH) 203
 Saponins 48, 50, 75, 98, 135, 145, 151, 169, 170, 171, 177, 205
 natural 75
 steroidal 151
 triterpenoid 145
 Secretion 4, 26, 27, 97, 99, 103, 105, 204
 colonic 103
 gastric acid 204
 glucose-stimulated insulin 99
 impaired insulin 4, 26, 27
 induced insulin 105
 natural insulin 97
 reducing glucose 97
 Serum 47, 48, 52, 71, 75, 129, 141, 142, 152
 cholesterol 47, 48, 75
 -clearance rates 52
 lipoproteins 142
 superoxide dismutase activity 75
 Serum glutamate 139
 oxaloacetate transaminase 139
 pyruvate transaminase 139
 Sesame 44, 50, 61, 81
 black 50
 white 50
 Sesame 43, 81
 lignans sesamol episesamin 43
 seed 81
Sesamum indicum 42, 43, 44, 50, 81
 Single 6, 153
 nucleotide polymorphisms (SNPs) 6
 oral administration of corosolic acid 153

Steroid therapy 3
 Stimulate 70, 109
 digestion 70
 glycolysis 109
 Stress 2, 8, 9, 11, 12, 21, 23, 28, 65, 129, 151
 biomechanical 151
 hormone 65
 kinases 12
 mental 129
 Stroke 68, 85, 130, 167
 Superoxide dismutase 45, 48, 81, 143, 146, 152
 cardiac 152
 Superoxide dismutase activity 200
 Synthesis 9, 10, 14, 19, 20, 72, 82, 138, 147
 excess collagen 147
 fatty acid 19
 lipid 20
 nucleotide 9
 phospholipid 10
 Synthetic antidiabetic drugs 96
 Systemic inflammatory effects 9
 Systolic blood pressure 64, 82, 130, 146, 203

T

Taraxacum officinale 42
 Targets 9, 110
 downstream 9
 pharmacological 110
 Target tissues 1, 13
 Terpenoids 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155
 biosynthesize 137
 in diabetes and cardiovascular diseases 139
 phytotherapy 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155
 synthase 137
 Therapies 26, 116
 anti-diabetic 26
 Toxicity 42, 146, 156, 189, 205
 arsenic 146
 hepatic 42
 moderate 205
 Traditional treatments for diabetes 40
 Trafficking 18, 20, 22
 cellular 22
 intracellular 20
 Transcriptional 10, 17, 19
 activity 19

effects 10, 17
Transcriptional factor 17, 51
 activity 17
 inhibitors 51
Transcriptional repressor 26, 27
 in liver cells 26
Transcription factors 6, 9, 12, 15, 17, 26
 activating 9
 phosphorylates 17
Transmission electron microscopy 150
Tumorigenesis 20
Tumour necrosis factor 12
Tyrosine autophosphorylation 15
Tyrosine kinase 12, 15, 16, 19, 20, 22, 28
 activity 15, 22
 antigen-related 20
 insulin receptor 19
 phosphorylation 12
 receptors 15, 28
Tyrosine phosphatases 16, 20, 153
 cytoplasmic protein 20
Tyrosine phosphorylation 15, 22, 23
 insulin-stimulated 22

U

Ulcer 203, 204
 indomethacin-induced 203
 indomethacin-induced gastric 204
Unfolded protein response (UPR) 10
Urine 25, 40, 66, 67, 141
 sugar levels 141
Ursolic acid 127, 135, 147, 148, 149, 194
 in cardiovascular diseases 148
 in diabetes 147
 oral treatment of 148

V

Vascular 46, 129, 168
 diseases 129, 168
 system 46
Vasodilatory activity of corosolic acid 155
Very-low-density lipoprotein (VLDL) 14

W

World Health Organisation (WHO) 2, 40, 41,
 61, 127, 128, 129, 156, 167

Wound healing 47, 141

Z

Zingiber officinale 85

“ Standing on the shoulders of giants, Professor Eddouks has crafted a nice book on phytotherapy. Shining light on the management of diabetes and hypertension, with many knowledge gaps being filled for phytotherapists. Every chapter has its merits.

*William Cho Biomedical Scientist
Hong Kong Precision Oncology Society, Hong Kong*

”

Mohamed Eddouks
Moulay Ismail University
Morocco

Mohamed Eddouks is Professor at Faculty of Sciences & Techniques Errachidia, Moulay Ismail University of Meknes, Morocco. His contribution to the field of medicinal plants includes 6 international books, 6 special issues in indexed international journals and more than 120 indexed peer-reviewed articles and 21 book chapters of international repute. He is classified by the reputed American database Expertscape among the top 3 experts in the world in the field of diabetes mellitus induced by streptozotocin (October, 2020). He has been awarded the first Prize of the Federation of Arab Scientific Councils in 2016 and the first Prize of Scientific Research of the Moroccan Association of Research and Development in 2008. He has been the founding Dean of Polydisciplinary Faculty of Errachidia, Morocco.